Additional file 1 of Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial
Creators: name: Wu, Wei
name: Chen, Jiewen
name: Deng, Heran
name: Jin, Liang
name: He, Zhanghai
name: Rao, Nanyan
name: Nie, Yan
name: Yao, Yandan
name: Yang, Yaping
name: Su, Fengxi
name: Liu, Jieqiong
Publisher: name: figshare
Year: 2021
Subjects: subject: Cell Biology
subject: Pharmacology
subject: Immunology
subject: FOS: Clinical medicine
subject: Cancer
subject: Science Policy
subject: Plant Biology
subject: FOS: Biological sciences

description: Additional file 1: Figure S1. Proportion of baseline blood lymphocyte subsets and the ratio of Tregs to CD4+ T, CD8+ T and NK cells in the neoadjuvant endocrine therapy (NET) and neoadjuvant chemotherapy (NAC) group. PBMCs before neoadjuvant treatment (baseline) were analyzed. Baseline percentages of CD4+ T cells (a), CD8+ T cells (b), Tregs (c), NK cells (d), B cells (e), CD4+ NKTs (f) and CD8+ NKTs (g), ratio of Tregs to CD4+ T cells (h), ratio of Tregs to CD8+ T cells (i) and ratio of Tregs to NK cells (j) in the NET and NAC group were shown as scatter plots. Statistical analyses were performed by Mann Whitney test and P&lt;0.05 was considered statistically significant. Figure S2. Neoadjuvant therapy-induced changes of blood lymphocyte subsets, ratio of Treg to CD8+ T and ratio of Treg to NK cell. PBMCs before neoadjuvant treatment (baseline) and after treatment were analyzed. a. Changes of CD4+ T cell among PBMCs after neoadjuvant endocrine therapy (NET) or neoadjuvant chemotherapy (NAC). b. Changes of percentage of Tregs among PBMCs after NET or NAC. c. Changes of percentage of NK cells among PBMCs after NET or NAC. d. Changes of percentage of CD4+ NKT cells among PBMCs after NET or NAC. e. Changes of ratio of Tregs to CD8+ T cells after NET or NAC. f. Changes of ratio of Tregs to NK cells after NET or NAC. Statistical analyses were performed by Wilcoxon matched-pairs signed rank test and P&lt;0.05 was considered statistically significant. Figure S3. Neoadjuvant therapy-induced changes of circulating tumor-specific CTLs. Blood samples at baseline and after neoadjuvant therapy were collected, and ELISPOT assays were performed to detect circulating tumor-specific CTLs (IFN-γ+ CTLs). Numbers of circulating tumor-specific CTLs before neoadjuvant treatment (baseline) and after treatment were analyzed. a. The number of baseline circulating tumor-specific CTLs (IFN-γ+ CTLs) between two groups were analyzed. b. Changes of circulating tumor-specific CTLs after neoadjuvant endocrine therapy (NET). c. Changes of circulating tumor-specific CTLs after neoadjuvant chemotherapy (NAC). Statistical analyses were performed by Mann Whitney test (a) or Wilcoxon matched-pairs signed rank test (b-c), and P&lt;0.05 was considered statistically significant. Figure S4. Neoadjuvant therapy-induced changes of tumor biomarkers. a. Baseline proportions of Ki67-positive tumor cells in tumor samples in the neoadjuvant endocrine therapy (NET) and neoadjuvant chemotherapy (NAC) group. b. Changes of number of CD8+ cells in tumor tissues of patients after NET. C. Changes of number of CD19+ cells in tumor tissues of patients after NET. Statistical analyses were performed by Mann Whitney test (a) or Wilcoxon matched-pairs signed rank test (b-c), and P&lt;0.05 was considered statistically significant. Figure S5. Associations between baseline proportions of blood lymphocyte subsets and therapeutic response in patients treated with neoadjuvant endocrine therapy (NET) or neoadjuvant chemotherapy (NAC). Baseline percentages of CD4+ T cells (a), CD8+ T cells (b), Tregs (c), NK cells (d), B cells (e), CD4+ NKTs (f) and CD8+ NKTs (g) from responders (PR) or non-responders (SD/PD) were analyzed. Statistical analyses were performed by Chi-square test and P&lt;0.05 was considered statistically significant. Figure S6. Associations between changes of proportions of blood lymphocyte subsets and therapeutic response in patients treated with neoadjuvant endocrine therapy (NET) or neoadjuvant chemotherapy (NAC). Changes of percentages of CD4+ T cells (a), CD8+ T cells (b), Tregs (c), NK cells (d), CD4+ NKTs (e) and CD8+ NKTs (f) from responders (PR) or non-responders (SD/PD) were analyzed. Statistical analyses were performed by Chi-square test and P&lt;0.05 was considered statistically significant. Figure S7. Associations between changes of proportions of Ki67-positive tumor cells in tumor tissues and therapeutic response in patients treated with neoadjuvant endocrine therapy (NET) or neoadjuvant chemotherapy (NAC). Changes of proportions of Ki67-positive tumor cells in tumor tissues in responders (PR) and non-responders (SD/PD) after (a) NET or (b) NAC were analyzed. Statistical analyses were performed by Chi-square test and P&lt;0.05 was considered statistically significant.